Joint Webinar: Ncardia & ACEA

25 June, 2018

Rethinking Translational Predictivity using HiPSC-Derived Models: A Retrospective Analysis for Cardiac Liabilities

Date & Time: June 28, 2018 at 15:30 - 16:30 (CEDT) / 09:30 EDT

Webinar recording

Thank you for attending our recent webinar! The webinar is now available for viewing below:


Human induced pluripotent stem cell (hiPSC)-derived models are heavily explored as alternatives for animal models used in preclinical discovery and safety assessment. Here, Jean-Pierre Valentin from UCB Biopharma will provide a retrospective review on three compounds which showed preclinical and clinical cardiac liabilities. To understand to what extend hiPSC-derived cardiomyocytes could have predicted their side effects, the three compounds were tested using Ncardia’s human iPSC-derived cardiomyocytes in combination with ACEA’s xCELLigence Cardio ECR system. The hiPSC-derived models demonstrated value in refining the integrated cardiac safety assessment.

Using real-time kinetic analysis, this physiologically-relevant human cardiac model allows for the detection of both acute as well as chronic drug-induced toxicities. In the last few years, this predictive validity of hiPSC-derived cardiomyocytes has also been substantiated by various case studies and publications. As a result, pharma are slowly integrating these assays into their early safety assessment to detect potential safety hazards and improve compound selection prior to entering the costly and time-consuming animal studies.

Read more: Ncardia ACEA Webinar 2018